... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Bladder cancer Non-muscle-invasive bladder cancer Prognosis Transurethral resection Tumor weight Transurethral resection of bladder tumors (TUR-BT...

...Huanglin Duan; Zanxuan Deng; Junrong Zou; Guoxi Zhang; Xiaofeng Zou; Tianpeng Xie Introduction: The current treatment of non-muscle-invasive bladder cancer is suboptimal. However, in recent years, hyperthermia intravesical chemotherapy (HIVEC) has emerged as a more effective alternative...

... Calmette-Guérin (BCG) intravesical instillation therapy, but optimal treatment has not yet been established. We retrospectively investigated the efficacy and safety of low-dose BCG therapy for non-muscle-invasive bladder cancer (NMIBC) and carcinoma in situ (CIS) in a multicenter study. Methods: From 1991...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Cystectomy Non-muscle-invasive bladder cancer Complications Morbidity Bladder carcinoma Urothelial neoplasm...

...Michele Zazzara; Arjan Nazaraj; Marcello Scarcia; Giuseppe Cardo; Roberto Carando; Giuseppe Mario Ludovico Background: Although TURB of tumor (TURBT) by itself can eradicate a non-muscle-invasive bladder cancer (NMIBC) completely, these tumors commonly recur and can progress to MIBC...

... in the treatment of non-muscle-invasive bladder cancer (NMIBC) recently, and here we report the relevant outcomes of our institution to evaluate its efficacy and safety. Methods: We retrospectively collected the data of NMIBC patients who underwent either TmLRBT or transurethral resection of bladder tumor (TURBT...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Non-muscle-invasive bladder cancer Bacillus Calmette-Guerin Recurrence Progression...

...Yegang Chen; Yongjiao Yang; Li Liu; Shangren Wang; Hong Song; Xiaoqiang Liu Objective: To investigate the relationship between the expression of tumor suppressor in lung cancer-1 (TSLC1) and clinicopathological characteristics of patients with non-muscle-invasive bladder cancer (NMIBC) and evaluate...

...Paolo Gontero; Arianna Gillo; Chiara Fiorito; Marco Oderda; Donatella Pacchioni; Giovanni Casetta; Francesca Peraldo; Andrea Zitella; Alessandro Tizzani; Fulvio Ricceri Objective: To determine the impact of prognostic factors of a series of high-grade Ta non-muscle-invasive bladder cancers (NMIBCs...

...Huixiang Yang; Huijie Li; Zhenchao Wang; Jing Gao; Yong Guo Objectives: To evaluate whether soluble Fas (sFas) in urine is an independent predictor of non-muscle-invasive bladder cancer (NMIBC). Methods: We performed a prospective chart review which included 128 subjects with NMIBC and 88 controls...

... in a homogeneous series of patients with non-muscle-invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guérin (BCG). Patients and Methods: 192 intermediate- and high-risk NMIBC cases were enrolled. The variables in study were age, stage, grade, focality, tumour size, presence of associated carcinoma...

...A. Volpe; M. Racioppi; L. Bongiovanni; D. D’Agostino; A. Totaro; A. D’Addessi; F. Marangi; G. Palermo; F. Pinto; E. Sacco; P.F. Bassi Objectives: Non-muscle-invasive bladder cancer is characterized by a high recurrence rate after primary transurethral resection. In case of bacillus Calmette-Guérin...

...: Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 2008;53:984–991. 21. Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al: Should all patients with non-muscle-invasive bladder cancer receive early intravesical...

... at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer...

... Introduction: Adherence to international guidelines is viewed as a prerequisite for optimal medical care delivery. Previously reported surveys for non-muscle-invasive bladder cancer (NMIBC) employed mailed questionnaires to urologists or patients resulting in conflicting degrees of agreement with existing...

... or resistance to chemotherapy. We evaluated the clinical significance of HO-1 expression in non-muscle-invasive bladder cancer. Patients and Methods: We examined 109 patients with non-muscle-invasive bladder cancer. The immunoexpression of HO-1, p53, and Ki-67 was analyzed using paraffin-embedded tissue from...

... (MMC) regimen. Patients and Methods: From September 2007 to November 2009, 40 consecutive evaluable patients with pathologically confirmed intermediate-risk non-muscle-invasive bladder cancer (NMIBC) were enrolled after complete transurethral resection of all visible tumors. The mean age...